Top 5 Stocks to Buy Now
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel Free NAII Stock Alerts

Natural Alternatives International (NAII) Competitors

Natural Alternatives International logo
$2.43 -0.05 (-2.02%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$2.44 +0.00 (+0.21%)
As of 06/24/2026 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NAII vs. EXOZ, INKT, CNTX, TCRX, and ANVS

Should you buy Natural Alternatives International stock or one of its competitors? MarketBeat compares Natural Alternatives International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Natural Alternatives International include eXoZymes (EXOZ), MiNK Therapeutics (INKT), Context Therapeutics (CNTX), TScan Therapeutics (TCRX), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry.

How does Natural Alternatives International compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

eXoZymes has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat eXoZymes' return on equity.

Company Net Margins Return on Equity Return on Assets
eXoZymesN/A -220.63% -141.26%
Natural Alternatives International -10.13%-12.21%-5.30%

eXoZymes has higher earnings, but lower revenue than Natural Alternatives International. eXoZymes is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eXoZymes$70K875.86-$9.16M-$1.14N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A

eXoZymes has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

32.4% of Natural Alternatives International shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Natural Alternatives International had 1 more articles in the media than eXoZymes. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company Overall Sentiment
eXoZymes Neutral
Natural Alternatives International Neutral

Summary

eXoZymes and Natural Alternatives International tied by winning 6 of the 12 factors compared between the two stocks.

How does Natural Alternatives International compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

MiNK Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. MiNK Therapeutics' return on equity of 0.00% beat Natural Alternatives International's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
Natural Alternatives International -10.13%-12.21%-5.30%

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 189.02%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Natural Alternatives International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

MiNK Therapeutics has higher earnings, but lower revenue than Natural Alternatives International. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 1 articles in the media. MiNK Therapeutics' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Natural Alternatives International
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

MiNK Therapeutics beats Natural Alternatives International on 8 of the 14 factors compared between the two stocks.

How does Natural Alternatives International compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Natural Alternatives International had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company Overall Sentiment
Context Therapeutics Neutral
Natural Alternatives International Neutral

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Context Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Context Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Context TherapeuticsN/A -59.95% -54.78%
Natural Alternatives International -10.13%-12.21%-5.30%

Context Therapeutics currently has a consensus target price of $6.17, indicating a potential upside of 970.60%. Given Context Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Context Therapeutics is more favorable than Natural Alternatives International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Context Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Context Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Natural Alternatives International has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Context TherapeuticsN/AN/A-$36.12M-$0.42N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A

Summary

Natural Alternatives International beats Context Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Natural Alternatives International compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Natural Alternatives International has higher revenue and earnings than TScan Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$10.32M5.58-$129.77M-$0.96N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, TScan Therapeutics had 6 more articles in the media than Natural Alternatives International. MarketBeat recorded 7 mentions for TScan Therapeutics and 1 mentions for Natural Alternatives International. TScan Therapeutics' average media sentiment score of 0.16 beat Natural Alternatives International's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TScan Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Natural Alternatives International
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 581.12%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe TScan Therapeutics is more favorable than Natural Alternatives International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Natural Alternatives International has a net margin of -10.13% compared to TScan Therapeutics' net margin of -1,360.61%. Natural Alternatives International's return on equity of -12.21% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-1,360.61% -91.94% -50.15%
Natural Alternatives International -10.13%-12.21%-5.30%

Summary

TScan Therapeutics beats Natural Alternatives International on 10 of the 16 factors compared between the two stocks.

How does Natural Alternatives International compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Natural Alternatives International has higher revenue and earnings than Annovis Bio. Natural Alternatives International is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.71N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A

Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 696.46%. Given Annovis Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Annovis Bio is more favorable than Natural Alternatives International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Natural Alternatives International had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company Overall Sentiment
Annovis Bio Neutral
Natural Alternatives International Neutral

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Annovis Bio has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -318.08% -215.47%
Natural Alternatives International -10.13%-12.21%-5.30%

Annovis Bio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Summary

Annovis Bio beats Natural Alternatives International on 7 of the 13 factors compared between the two stocks.

Get Natural Alternatives International News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAII and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAII vs. The Competition

Export
MetricNatural Alternatives InternationalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.56M$2.99B$6.74B$12.32B
Dividend YieldN/A1.78%2.68%5.88%
P/E Ratio-1.0218.6525.3723.95
Price / Sales0.12341.96530.17107.90
Price / CashN/A56.6445.2953.76
Price / Book0.224.1410.766.41
Net Income-$13.57M$64.45M$3.56B$337.14M
7 Day Performance-8.99%1.22%0.99%-1.06%
1 Month Performance-4.71%0.95%0.79%0.49%
1 Year Performance-28.74%25.22%30.25%28.43%

Natural Alternatives International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAII
Natural Alternatives International
0.5193 of 5 stars		$2.43
-2.0%		N/A-28.5%$15.56M$129.86MN/A290
EXOZ
eXoZymes
0.3274 of 5 stars		$7.42
+1.0%		N/A-29.9%$62.91MN/AN/A29
INKT
MiNK Therapeutics
2.9048 of 5 stars		$11.81
-5.7%		$35.00
+196.4%		+65.9%$62.45MN/AN/A30
CNTX
Context Therapeutics
2.8423 of 5 stars		$0.65
-4.2%		$6.17
+848.3%		+0.0%$62.40MN/AN/A7
TCRX
TScan Therapeutics
3.6536 of 5 stars		$0.85
-10.8%		$6.00
+607.5%		-47.6%$62.11M$10.32MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NAII) was last updated on 6/25/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel